---
title: "Asahi Kasei Optimizes Material Portfolio Through Supply Realignment by FY2030"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286103445.md"
description: "Tokyo-based Asahi Kasei, a diversified global company, revealed intentions to streamline operations at its Mizushima Works facility by fiscal year 2030."
datetime: "2026-05-12T12:35:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286103445.md)
  - [en](https://longbridge.com/en/news/286103445.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286103445.md)
generator: "portal-rs"
---

# Asahi Kasei Optimizes Material Portfolio Through Supply Realignment by FY2030

Tokyo-based Asahi Kasei, a diversified global company, revealed intentions to streamline operations at its Mizushima Works facility by fiscal year 2030.

### Related Stocks

- [3407.JP](https://longbridge.com/en/quote/3407.JP.md)
- [AHKSY.US](https://longbridge.com/en/quote/AHKSY.US.md)

## Related News & Research

- [Asahi Kasei Microdevices current sensors power Microchip ML arc fault detection design](https://longbridge.com/en/news/298248640.md)
- [Asahi Kasei unit Veloxis doses first patient in Phase 2 kidney transplant trial of pegrizeprument](https://longbridge.com/en/news/297513882.md)
- [Asahi Kasei targets 10 new license deals in FY2025-27, aims for JPY 10 billion profit by around 2030](https://longbridge.com/en/news/296423590.md)
- [Asahi Kasei releases transcript from Q1 FY2026 financial results briefing Q&A session](https://longbridge.com/en/news/295605446.md)
- [Asahi Kasei says Japan approves Empaveli for C3 glomerulopathy, immune complex MPGN](https://longbridge.com/en/news/296747787.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**